Kornimate/medical-research-clean huggingface dataset:
a dose escalation study in solid tumors and a dose expansion study of prn1371 in adult patients with metastatic urothelial carcinoma

Conditions: Solid Tumors; Metastatic Urothelial Carcinoma & Renal Pelvis & Ureter

Summary: this is a multi-center, open label, non-randomized phase 1 study, to be conducted in two parts, part a, and part b. part a in solid tumors included the dose escalation phase for evaluating the safety and tolerability profile of prn1371, a fgfr 1-4 kinase inhibitor. part b is the cohort expansion phase in patients with metastatic urothelial carcinoma to further evaluate safety and tolerability, preliminary activity, pk, and pd in patients with fgfr genetic alterations.

the protocol specifies rules for dose-limiting toxicity and a maximum tolerated dose (mtd). to gain further experience with the mtd, and/or at some lower optimal biologic dose level, an expansion cohort (part b) enrolled patients with metastatic urothelial carcinoma with fibroblast growth factor receptor (fgfr) 1, 2, 3 or 4 genetic alterations.

Eligibility criteria:
inclusion criteria: * age ≥ 18 years * histological or cytological documentation of an advanced solid tumor * subject must have metastatic or recurrent disease and have failed first-line systemic treatment, and if indicated, failed approved second-line therapy, and for whom no standard therapy options are anticipated to result in a durable remission * subject must have evaluable, progressive, and measurable disease per the response evaluation criteria in solid tumors (recist) guidelines, version 1.1 * adequate bone marrow, liver, and renal function * patient has an eastern cooperative oncology group (ecog) performance status ≤ 1 for part b (expansion) in subjects metastatic urothelial carcinoma: * the patient's tumor has been evaluated and prospectively identified as having fgfr 1, 2, 3, or 4 genetic alterations. exclusion criteria: * patients who have received adequate prior treatment with a highly selective fgfr inhibitor * patients with other major uncontrolled medical conditions, e.g., recent myocardial infarction, stroke, diabetes, active hepatitis * patients who have received prior systemic anticancer therapy ≤ 3 weeks prior to study start (6 weeks for nitrosourea, antibodies, or mitomycin-c) * patients diagnosed with another primary malignancy within 3 years prior to study start, with the exception of adequately treated basal cell carcinoma, squamous cell carcinoma, or other non-melanomatous skin cancer, or carcinoma in situ of the uterine cervix * patients with glioblastoma multiforme * patient has a primary neoplasm of the brain or known uncontrolled metastases to the central nervous system (cns).

Keywords: fgfr
smart glasses in emergency medicine from the hangzhou asian games

Conditions: Trauma Injury; Acute Coronary Syndrome; Stroke, Acute; Septic Shock

Summary: the findings of our study will reveal that using smart glasses in the emergency department(ed) could facilitate patient admission. ar smart glasses offer the potential to enhance the effectiveness and speed of treatment within ed.

study design: this study will be conducted at sir run run shaw hospital (srrsh), china. this study aims to compare the outcomes of two groups: the intervention group, utilizing the augmented reality (ar) smart glasses, and the control group, adhering to the standard conventional triage process without the ar tool, only using a two-way radio connection. augmented reality tool the ar tool used in this study will be a smart glasses manufactured by rokid ar studio(hangzhou, china). it was rokid glass 2 model released in 2020. the device operated on android 9.0 and it connected to 5g connection with a bandwidth speed 30-mbps delivering a very low latency. the device supported real time screen sharing and therefore the data were collected from smart glasses including visual and audio with real-time two-way communications. physicians at the hospital can access the information and video via a mobile app, enabling continuous monitoring of patients. the features facilitate healthcare providers at srrsh and medical personnel in the hag2022 polyclinic to discuss the patient's condition, exchange, and deliberate on the pre-hospital medical examinations of the patient. participants: the study, will be conducted between september 13, 2023, and october 28, 2023, included the recruitment of all patients (older than 16 years old) presenting with acute illnesses who were admitted to the ed of srrsh from the hag2022 village polyclinic or the field of injury. the cases with incomplete data and cases where the patients would be not found will be excluded from this study. cases involving technical difficulties encountered by operators using augmented reality (ar) smart glasses and loss of internet connection will be excluded from the study.

Eligibility criteria:
inclusion criteria: * presenting with acute illnesses like acute coronary syndrome，acute sepsis，stroke，trauma who will be admitted to the ed of srrsh from the hag2022 village polyclinic or the field of injury. exclusion criteria: * the cases with incomplete data and cases where the patients will be not found will be excluded from this study. cases involving technical difficulties encountered by operators using augmented reality (ar) smart glasses and loss of internet connection will be excluded from the study.

Keywords: telemedicine tele-consultation smart glasses emergency medicine
comparative study of quietcare

Conditions: Elderly People; Living Alone in a Residence With Care Giver

Summary: the objective of the study is to examine the efficacy and safety of quietcare in a randomized, open study in elderly subjects living in assisted/ independent living facilities for 6 months.


Eligibility criteria:
inclusion criteria: 1. ability to move independently or by using a walker (without assistance) inside 2. residents using a single room, age 65 or older, of either sex exclusion criteria: * people who use wheel chairs, * people who are bed-ridden

Keywords: elderly fall acute illness care giver
computer assisted selection of serrated adenomas and neoplastic polyps - a new clinical draft

Conditions: Polyps; Adenoma Colon; Automatic Judgement; Colonic Neoplasms

Summary: the aim of the study is to develop a computer program which is able to classify different entities of colorectal polyps on the basis of optical polyp features. in the end, the computer program shall differentiate between (i) hypeplastic polyps, (ii) adenomas and (iii) serrated adenomas . in the first phase of the study a computer program will be established which aims to distinguish between the above mentions entities on the basis of optical features derived from still images. a machine learning apporach will be used for creating the program. afterwards, in a second phase of the study, still images of 100 polyps (not used in the first phase) will be presented to the computer program. quality of the computer program will be tested by calculating the accuracy for differentiating the three different polyp types. the gold standard for true polyp diagnoses will be based on histopathological diagnoses of the polyps. the same pictures of 100 polyps will also be presented to human experts. experts will also predict histopathological diagnoses on the basis of optical polyps featurs. accuracy of computer-decisions and human expert predictions will be compared. the establishment of a well- functioning computer program is the primary aim of the study.


Eligibility criteria:
inclusion criteria: * indication for colonoscopy * patients \>= 18 years exclusion criteria: * pregnant women * indication for colonoscopy: inflammatory bowel disease * indication for colonoscopy: polyposis syndrome * indication for colonoscopy: emergency colonoscopy e.g. acute bleeding * contraindication for polyp resection e.g. patients on warfarin
linked color imaging vs white light imaging for detection of gastric cancer precursors

Conditions: Early Gastric Cancer; Barrett Esophagus

Summary: this study aims to examine the use of linked color imaging in detection of gastric cancer precursors, as well as oesophageal and duodenal lesions.

gastric cancer is the fifth most common cause of death worldwide. early detection and removal of gastric cancer precursors and early gastric cancer is crucial for good outcomes. however, these lesions are subtle and often missed by conventional white light imaging (wli) endoscopy. image enhanced endoscopy techniques have been developed to enhance the detection and characterization of gastrointestinal lesions. narrow band imaging (nbi) is one such technique. though widely used, its drawbacks include a limited far view as a result of the optical filter causing a dark endoscopic view. linked color imaging (lci) is a more recent image enhanced endoscopy technique that acquires images by using both narrow-band wavelength light and white light in an appropriate balance, enhancing slight color differences in the red region of mucosa. it has been proven to improve detection of h pylori gastritis and colorectal neoplasms. thus far, there has been no study to determine whether the use of lci will increase the detection rate of gastric cancer precursors and early gastric cancer compared to wli. this study aims to determine whether lci can increase the detection rate of gastric cancer precursors and early gastric cancer when compared to white light endoscopy, with the null hypothesis being no difference in detection rates. this study will also examine the use of lci with magnification to predict histology findings for focal lesions seen on endoscopy, as well as the use of lci in identifying esophageal lesions (such as barett's esophagus) and duodenal lesions.

Eligibility criteria:
inclusion criteria: * patients aged 50 years and above * patients undergoing gastroscopy for symptom evaluation * patients undergoing gastroscopy for surveillance of known intestinal metaplasia exclusion criteria: * emergent gastroscopy performed for suspected acute gi bleeding * patients with previous surgical/endoscopic resection in stomach * patients with deranged coagulation and platelet function (inr\>1.5, plt\<50) * patients with severe comorbid illness (asa 3 and above)
a randomized control trial for patient reported outcomes and safety in outpatient thyroid lobectomy

Conditions: Thyroid Lobectomy

Summary: to compare same-day discharge and overnight (or longer) observation practices and learn more about the differences in patient preferences, safety outcomes, and economic and resource impact

primary objective: --to determine whether same-day discharge is non-inferior to usual care (overnight stay) with regard to the md anderson symptom inventory - thyroid (mdasi-thyroid) mean severity score, as assessed at 2 weeks post-procedure in patients undergoing thyroid lobectomy. secondary objectives: * to determine whether same-day discharge is non-inferior to usual care (overnight stay) with regard to the mdasi-thyroid mean severity score, as assessed at 24 hours post-procedure in patients undergoing thyroid lobectomy. * to determine whether the two arms differ by incidence of deviations from normal as defined by post-operative hematoma, emergency care presentation, readmission/re-intervention, high pain severity scores, and 30-day mortality. * to determine whether morphine milligram equivalents (mme) used over the 2-week post-operative period differs between patients who receive same-day discharge vs. those who receive usual care (overnight stay) after receiving thyroid lobectomy.

Eligibility criteria:
inclusion criteria: 1. patients ≥18 years of age 2. patients undergoing initial partial or complete thyroid lobectomy 3. english and non-english speaking patients are eligible exclusion criteria: 1. increased risk of bleeding (e.g., aspirin, antiplatelet therapy, or anticoagulation that cannot be held 5 days before surgery, baseline thrombocytopenia \<50,000/µl) 2. pre-existing medical comorbidities or poor performance status (eastern cooperative oncology group performance status \>2) that would otherwise dictate overnight in-hospital postoperative observation 3. increased distance of residence from index hospital (\>50 miles) or inability to stay within the targeted area (\<50 miles) postoperatively prohibiting timely return to the index hospital in emergent situations 4. lives alone or unable to independently perform activities of daily living and no available caregiver in the immediate postoperative period (pod 0-3) 5. pregnant women will not be included in this study
kinesio taping with &without craniosacral therapy in pregnant females with sij dysfunction.

Conditions: Sacral Disorder

Summary: sij dysfunction adversely affects quality of life and causes functional impairment and disability. although, k taping and craniosacral therapy were previously affective in treating si joint dysfunction, the combined affects of these intervention have not been compared previously to k taping alone.

this study is a randomized controlled trial and have 30 pregnant women suffering from sijh dysfunction. there is 2 groups and both have received treatment for 6 weeks. the data on pain is collected through vas and the data on disability is collected through oswestry disability index, and data on quality of life will be collected using sf-36. measurements will be taken at the beginning of the study and at the end of the 4th week, at the completion of the study. data will be analyzed using spss.

Eligibility criteria:
inclusion criteria: * age between 18-35 * pregnant females in 3rd trimester * pregnant females with sij dysfunction exclusion criteria: * high risk pregnancy * pregnant females with hypermobility syndrome * previous pelvic history

Keywords: sacro-iliac dysfunction
cardiac function non-invasive monitoring system evaluation trial

Conditions: Cardiac Disease

Summary: non-significant risk device study to conduct evaluation of the performance of new device for monitoring of cardiac function (based on previous iterations 510(k) 173156)

non-significant risk device study to conduct evaluation of the performance of new device for monitoring of cardiac function (based on previous iterations 510(k) 173156)

Eligibility criteria:
inclusion criteria: * adults of age 18 or older exclusion criteria: * subjects with wounds or surgical incisions at the site of sensor placement
evaluate the efficacy and safety of jmkx003002 in end-stage renal disease patients on hemodialysis with hyperphosphatemia

Conditions: Hyperphosphatemia

Summary: a phase 2a, multicenter, randomized, open-label, active drug-controlled trial to evaluate the efficacy and safety of jmkx003002 in end-stage renal disease patients on hemodialysis with hyperphosphatemia

evaluate the efficacy and safety of jmkx003002 in end-stage renal disease patients on hemodialysis with hyperphosphatemia

Eligibility criteria:
inclusion criteria: 1. able to understand the procedures of this trial and provide written informed consent voluntarily; 2. age ≥ 18 years, male or female; 3. on a stable hemodialysis regimen at a frequency of two or three times per week for at least 12 weeks prior to the screening visit; 4. serum phosphorus within the trial-required range. exclusion criteria: 1. any history of inflammatory bowel disease or diarrheal irritable bowel syndrome; 2. pregnant or breastfeeding; 3. any history of a parathyroid intervention; 4. diarrhea or loose stools occurred within 1 week prior to randomization.
mf-4181 for the reduction of scars secondary to abdominoplasty or laparoscopy/laparotomy gynecologic procedures

Conditions: Scars

Summary: the objective of the study is to evaluate the safety and preliminary efficacy of mf-4181, a hydrogel scaffold, in improving scars and their resulting consequences following abdominoplasty or laparoscopy/laparotomy gynecologic procedures.


Eligibility criteria:
inclusion criteria: * male or female subjects between 18 and 60 years of age undergoing abdominoplasty without intraoperative flexion at time of skin excision or female subjects between 18 and 60 years of age undergoing diagnostic and/or operative laparoscopy/laparotomy gynecologic procedures. * weight between 50 and 95 kg with bmi between 20 and 30 * able and willing to give written informed consent * willing to comply with the follow-up schedule exclusion criteria: * need of concomitant surgical procedures that would be performed at the same time as the index surgical procedure or that would influence the healing process * previous abdominal surgery with scars or adhesions that would limit or complicate the index surgical procedure * presence of ventral or umbilical hernia requiring the use of prosthetic material * heart disease * pregnant or planning to become pregnant during the course of the study; the exception to this exclusion is if ectopic pregnancy is the reason for the procedure * history of coagulopathy or bleeding disorder * an american society of anesthesiologists (asa) score of \>ii * known diabetes * current or history of heavy smoking (i.e., 10 pack years) * active skin disorder or other condition that may interfere with healing or history of such a condition * planned use of an on-q® pain control device (i-flow corporation, lake forest, ca) or similar incisional intervention post index procedure * active collagen vascular disease or vasculitis, e.g., systemic lupus erythematosus, polyarteritis, dermatomyositis, systemic scleroderma or thrombotic thrombocytopenic purpura * anticipated use of dermabond® or another topical skin adhesive type of wound closure * unwilling or unable to return for follow-up visits * regular, continuous use of systemic corticosteroid therapy or topical corticosteroid use in the area to be treated * current participation or participation within the last 3 months in the study of an investigational drug, device, or biologic * unable or unwilling to follow post-operative instructions * known hypersensitivity to mf-4181, dextran, or any of its constituent materials * previous participation in this study to avoid multiple enrollments of an individual subject. * chemotherapy or hormone therapy for cancer within the last 3 months, or probability that these treatments will be required during the 6 months of study participation. * current or past radiation therapy in the abdominal incision
the impact of integrative medicine on patient-reported outcomes in management of chronic pelvic pain

Conditions: Chronic Female Pelvic Pain Syndrome (Disorder)

Summary: the purpose of this research is to determine if mind and body counseling and training improves quality of life in women undergoing treatment for chronic pelvic pain.

patients with chronic illnesses are expected to self-manage much of their treatment. barriers include limited time during appointments, consultations with multiple different providers, technical communication style, health literacy issues, and a sense of feeling overwhelmed. patients with chronic pain syndromes experience symptoms which can negatively impact their quality of life by interfering with ability to sleep, work, and function in their social roles. one proposed mechanism in chronic pain management is mindfulness. mindfulness is the intentional and non-judgmental conscious awareness of the present moment, or "paying attention on purpose" with the goal of physical and psychological health improvement. participants are taught autonomy, increasing self-regulation, and focusing awareness on a particular goal or activity. the investigators hypothesize that a mind-body counselor will improve patient engagement and promote adherence to pain coping treatments. if the initial findings from this project support the use of integrative medicine services in women with chronic pelvic pain, the investigators hope to expand this study to a larger, randomized controlled trial that is adequately powered to determine significant difference among participants in the control and study groups.

Eligibility criteria:
inclusion criteria: * clinical diagnosis of chronic pelvic pain. * must speak english. * must be ages 18 through 89. * must be willing and able to provide informed consent for participation. * must have access to the patient online services portal to complete the questionnaires. exclusion criteria: - diagnoses of primarily non-gynecologic pain, acute pelvic pain, and active abdominal or pelvic malignancy.
the influence of soy isoflavnoids on the hypocholesterolemic effects of soy

Conditions: Hyperlipidemia; Cardiovascular Diseases

Summary: isoflavonoids, through their estrogen-like activity, are in part responsible for the cholesterol lowering properties of soy foods. if this is found to be so, then it would be advantageous not only to promote soy consumption, but also to identify and use soy cultivars with high isoflavonoid content in production of soy food products. these foods may have a use in the reduction of serum cholesterol and if they effectively increase the phytoestrogen activity of soy, may have a role in the prevention of other hormone dependent diseases (e.g. osteoporosis, certain cancers) in the same way as natural estrogens.


Eligibility criteria:
inclusion criteria: * men and post-menopausal women * ldl-c \> 4.1mmol/l at recruitment * living within a 40 km radius of st. michael's hospital exclusion criteria: * lipid lowering medications * clinical or biochemical evidence of diabetes, renal or hepatic disease * body mass index (bmi) \>38 kg/m2 * antibiotic use within the last three months * hormone replacement therapy * smoking or significant alcohol use (\>1 drink/d) * triglyceride level \> 4.0mmol/l

Keywords: diet therapy
rectal dexmedetomidine niosomes for postoperative analgesia in pediatric cancer patients.

Conditions: Postoperative Pain

Summary: applying nanotechnology in drug delivery systems improved the bioavailability and kinetic profile of drugs in biological systems

nanotechnology which is focused on studying the properties and the applications of materials with structure size in the range of 1-100 nm has been widely used in various fields. in biomedical research fields, nanotechnology has been used to design and development of drug delivery systems (ddss). nanotechnology-based drug delivery systems (nddss) offer many potential advantages in cancer treatment, such as improving targeting of the therapeutic drugs, protecting drugs from degradation during in vivo transport, controlled drug release at specific sites or cells in response to specific signals, and thus improving the therapeutic efficacy while minimizing side effects. applying nanotechnology in drug delivery systems improved the bioavailability and kinetic profile of drugs in biological systems. advances in nanotechnology aid in targeting drugs to specific molecular targets and safely delivering drugs to specific sites of action. the sustained release of nano-drug delivery systems enhances the controlled release profile of loaded drugs, thereby minimizing the dosage-regimen. the aim of this study will be to investigate the population pharmacokinetics and pharmacodynamics of rectal dexmedetomidine niosomes for postoperative analgesia in pediatric cancer patients undergoing bone marrow biopsy and aspiration in comparison with the intravenous and rectal plain formulation.

Eligibility criteria:
inclusion criteria: * asa physical status i and ii. * aged 3-7 yrs. * undergoing bone marrow aspiration and biopsy. exclusion criteria: * allergy to the study drugs. * significant organ dysfunction. * cardiac dysrhythmia. * congenital heart disease. * use of psychotropic medication. * mental retardation.